(MedPage Today) — GLP-1 agonists may have little impact on risk of obesity-related cancers, according to a systematic review and meta-analysis of randomized studies. (Annals of Internal Medicine)
The FDA granted accelerated approval for the subcutaneous…
Global study reveals how psychedelics dissolve the brain’s hierarchy
New neuroimaging research suggests that multiple psychedelics affect the brain in a similar way, revealing something like the ‘core signature’...






